# Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer

> **NCT02831582** · NA · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Arthralgia
- Breast Neoplasms

## Interventions

- **DIETARY_SUPPLEMENT:** Omega-3 Fatty Acid
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02831582
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-12
- **Primary completion:** 2021-12-11
- **Final completion:** 2021-12-11
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831582, "Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02831582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*